Alnylam Pharma (ALNY) Says DMC Recommends Continuation of Phase 3 APOLLO Trial
Go back to Alnylam Pharma (ALNY) Says DMC Recommends Continuation of Phase 3 APOLLO Trial| Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) | Delayed: 143.80 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $143.80 | 52 Week High | $109.10 | |||
| Open | $143.80 | 52 Week Low | $31.38 | |||
| Day High | $143.80 | P/E | N/A | |||
| Day Low | $143.80 | EPS | $-1.45 | |||
| Volume | 61 | |||||
